Molecular Stock Forum

$Molecular (MOLN.US)$
Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced an upcoming presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic (RDT) targeting DLL3 for Small Cell Lung Cancer, at the European Association of Nuclear Medicine (EANM) Congress in Hamburg, Germany, Octo...

$Molecular (MOLN.US)$  Will be watching to see what happens. They are pretty healthy books but aren't terribly close to market on anything yet? 🤔

$Neo-Concept International (NCI.US)$ Uptrending. Borrow rate doubled Friday. Breakout is at .90. Trend is based on acquisition news.
$Boqii (BQ.US)$ Short sellers are slowly covering until breakout at .67 it appears. After that resistance is at 1.00 and 2.22.
$Senstar Technologies (SNT.US)$ No resistance will move up until shorts decide to pull it back.
$Molecular (MOLN.US)$  Same as SNT.
$Borealis Foods (BRLS.US)$ Highest borrow rate on market. Will run very soon and reach...

$Molecular (MOLN.US)$
👍👍👍

$Molecular (MOLN.US)$
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
Molecular Partners has presented the final data from its Phase 1 trial of MP0317, a CD40 agonist, at the ASCO 2024 Annual Meeting. The study included 46 patients with advanced solid tumors and showcased favorable safety and promising efficacy. MP0317 was shown to localize within the tumor microenvironment (...

$Molecular (MOLN.US)$
NEWS
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action 
Preclinical data shows preferential T cell-mediated killing of AML cells by MP0533 while sparing healthy cells.
MP0533 induces tumor regression and T-cell activation without systemic adverse effects.
The data supports the clinical development of MP0533 as a potential treatment for acute myeloid leukemia.
The ongoing Phase 1/2a clin...

$Molecular (MOLN.US)$ strong rejection 460 market condition against TA not interested overextended further downside may be

The consistancy over the past year is a charm for those wanting to buy and sale without long holds. A lot of play when grabbed at or below $6 with PT $7 or above. Catch it while you can! $Molecular (MOLN.US)$

$Molecular (MOLN.US)$
happy growing, just like a garden it requires patience and strategy.